Clinical Research Directory
Browse clinical research sites, groups, and studies.
Comparative Efficacy of Apremilast and Acitretin in Moderate-to-Severe Hidradenitis Suppurativa
Sponsor: Hayat Abad Medical Complex, Peshawar
Summary
This randomized controlled trial compares the efficacy of oral apremilast and oral acitretin in the treatment of moderate-to-severe hidradenitis suppurativa. Seventy eligible adults were randomly assigned to receive either apremilast (30 mg twice daily) or acitretin (25 mg twice daily) for 12 weeks. The primary outcome was improvement in disease severity measured using the International Hidradenitis Suppurativa Severity Score System (IHS4). The study aims to determine which treatment provides greater clinical improvement and may help guide treatment decisions for patients with moderate-to-severe hidradenitis suppurativa.
Key Details
Gender
All
Age Range
18 Years - 40 Years
Study Type
INTERVENTIONAL
Enrollment
70
Start Date
2024-12-22
Completion Date
2025-05-22
Last Updated
2026-07-16
Healthy Volunteers
No
Conditions
Interventions
Apremilast
Oral apremilast 30 mg administered twice daily for 12 weeks in participants with moderate-to-severe hidradenitis suppurativa
Acitretin
Oral acitretin 25 mg administered twice daily for 12 weeks in participants with moderate-to-severe hidradenitis suppurativa
Locations (1)
Medical Teaching Institution-Lady Reading Hospital
Peshawar, Khyber Pakhtunkhwa, Pakistan